CN1073103C - 用于治疗与类胰蛋白酶活性有关的疾病的新化合物和组合物 - Google Patents

用于治疗与类胰蛋白酶活性有关的疾病的新化合物和组合物 Download PDF

Info

Publication number
CN1073103C
CN1073103C CN97196877A CN97196877A CN1073103C CN 1073103 C CN1073103 C CN 1073103C CN 97196877 A CN97196877 A CN 97196877A CN 97196877 A CN97196877 A CN 97196877A CN 1073103 C CN1073103 C CN 1073103C
Authority
CN
China
Prior art keywords
base
compound
alkylidene group
alkyl
inferior
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN97196877A
Other languages
English (en)
Chinese (zh)
Other versions
CN1226892A (zh
Inventor
杰弗里·M·登纳
伊莱恩·伊玲·库
肯·D·赖斯
维维安·鲁然·旺
温迪·贝思·扬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axys Pharmaceuticals Inc
Original Assignee
Arris Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharmaceutical Corp filed Critical Arris Pharmaceutical Corp
Publication of CN1226892A publication Critical patent/CN1226892A/zh
Application granted granted Critical
Publication of CN1073103C publication Critical patent/CN1073103C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/14—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
CN97196877A 1996-07-30 1997-07-30 用于治疗与类胰蛋白酶活性有关的疾病的新化合物和组合物 Expired - Fee Related CN1073103C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2313996P 1996-07-30 1996-07-30
US60/023,139 1996-07-30
US89577297A 1997-07-17 1997-07-17
US08/895,772 1997-07-17

Publications (2)

Publication Number Publication Date
CN1226892A CN1226892A (zh) 1999-08-25
CN1073103C true CN1073103C (zh) 2001-10-17

Family

ID=26696778

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97196877A Expired - Fee Related CN1073103C (zh) 1996-07-30 1997-07-30 用于治疗与类胰蛋白酶活性有关的疾病的新化合物和组合物

Country Status (17)

Country Link
EP (1) EP0934293A1 (cs)
JP (1) JP2001509787A (cs)
KR (1) KR20000029679A (cs)
CN (1) CN1073103C (cs)
AU (1) AU733621B2 (cs)
CA (1) CA2262542A1 (cs)
CZ (1) CZ29799A3 (cs)
EE (1) EE9900036A (cs)
FI (1) FI990171A7 (cs)
HU (1) HUP0003267A3 (cs)
LV (1) LV12291B (cs)
NO (1) NO990433L (cs)
NZ (1) NZ333713A (cs)
PL (1) PL331465A1 (cs)
SI (1) SI9720047A (cs)
SK (1) SK8599A3 (cs)
WO (1) WO1998004537A1 (cs)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
US6613769B1 (en) * 1998-02-06 2003-09-02 Max-Planck-Gesellschaft zur Föderung der Wissenschaften. e.V. Tryptase inhibitors
US6489327B1 (en) * 1998-02-06 2002-12-03 Max-Planck-Gesellschaft Zur Fordrungder Wisenschaften, E.V. Tryptase inhibitors
CA2342855A1 (en) * 1998-09-04 2000-03-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel pyranoses
WO2001010848A2 (en) * 1999-08-10 2001-02-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Diazocin-dione derivatives and their use s tryptase inhibitors
EP1216236A1 (en) * 1999-09-14 2002-06-26 Byk Gulden Lomberg Chemische Fabrik GmbH Tryptase inhibitors
WO2001036386A1 (en) * 1999-11-17 2001-05-25 Sumitomo Pharmaceuticals Co., Ltd. Diabetic remedy containing dipiperazine derivative
DE19955476A1 (de) * 1999-11-18 2001-05-23 Boehringer Ingelheim Pharma Bis-basische Verbindungen als Tryptase-Inhibitoren, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DK1244614T3 (da) 1999-12-20 2004-09-27 Altana Pharma Ag Tryptase-inhibitorer
JP2003518109A (ja) * 1999-12-20 2003-06-03 アルタナ ファルマ アクチエンゲゼルシャフト トリプターゼ阻害剤
ATE273302T1 (de) * 2001-01-31 2004-08-15 Altana Pharma Ag Diazocinderivate und deren verwendung als tryptase inhibitoren
ES2278913T3 (es) 2001-02-21 2007-08-16 Altana Pharma Ag Agentes inhibidores de triptasas.
AU2002253026B2 (en) * 2001-02-21 2007-08-09 Altana Pharma Ag Tryptase inhibitors
EP1370518A2 (en) * 2001-03-15 2003-12-17 ALTANA Pharma AG Tryptase-inhibitors
WO2002074732A2 (en) * 2001-03-15 2002-09-26 Altana Pharma Ag Tryptase-inhibitors
CA2449729C (en) 2001-06-11 2009-11-03 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
WO2002102771A1 (en) 2001-06-19 2002-12-27 Altana Pharma Ag Tryptase inhibitors
WO2006050514A1 (en) 2004-11-04 2006-05-11 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
TWI432188B (zh) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
JP5385402B2 (ja) 2008-12-19 2014-01-08 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン 肥満細胞媒介疾患を治療するための１−アミノ−アルキルシクロヘキサン誘導体
FR3038605B1 (fr) 2015-07-06 2018-08-24 Universite Amiens Picardie Jules Verne Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation
US12275687B2 (en) 2017-05-12 2025-04-15 Riken Class A GPCR-binding compound modifier

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032945A1 (en) * 1994-06-01 1995-12-07 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell mediated conditions
WO1996009297A1 (en) * 1994-09-23 1996-03-28 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell inflammatory condition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
SK282537B6 (sk) * 1993-03-12 2002-10-08 Axys Pharmaceuticals, Inc. Inhibítor tryptázy alebo jeho farmaceuticky prijateľná soľ, farmaceutický prostriedok s jeho obsahom a jeho použitie
KR19980703261A (ko) * 1995-03-24 1998-10-15 다니엘 이이치. 페트리 가역성 프로테아제 억제제
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032945A1 (en) * 1994-06-01 1995-12-07 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell mediated conditions
WO1996009297A1 (en) * 1994-09-23 1996-03-28 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell inflammatory condition

Also Published As

Publication number Publication date
HUP0003267A2 (hu) 2001-06-28
LV12291B (en) 2000-04-20
EE9900036A (et) 1999-08-16
JP2001509787A (ja) 2001-07-24
WO1998004537A1 (en) 1998-02-05
KR20000029679A (ko) 2000-05-25
SI9720047A (sl) 1999-08-31
CA2262542A1 (en) 1998-02-05
LV12291A (lv) 1999-06-20
CZ29799A3 (cs) 1999-06-16
SK8599A3 (en) 2000-03-13
HUP0003267A3 (en) 2002-02-28
FI990171A0 (fi) 1999-01-29
PL331465A1 (en) 1999-07-19
NZ333713A (en) 2000-12-22
CN1226892A (zh) 1999-08-25
NO990433L (no) 1999-03-25
FI990171L (fi) 1999-03-23
FI990171A7 (fi) 1999-03-23
EP0934293A1 (en) 1999-08-11
NO990433D0 (no) 1999-01-29
AU733621B2 (en) 2001-05-17
AU3967097A (en) 1998-02-20

Similar Documents

Publication Publication Date Title
CN1073103C (zh) 用于治疗与类胰蛋白酶活性有关的疾病的新化合物和组合物
CN1110305C (zh) 作为抗凝剂的萘基取代的苯并咪唑衍生物
CN1243751C (zh) 用作抗变态反应药物的哌啶化合物
CN100337626C (zh) 酰化的、杂芳基－稠合的环烯基胺和它们作为药物的用途
CN1298715C (zh) 作为组胺h3拮抗剂的非咪唑化合物
CN1207289C (zh) 金属蛋白酶抑制剂,含有它们的药物组合物和其药物用途,其制备方法和中间体
CN1117082C (zh) 具有抗癌和细胞活素抑制活性的取代咪唑类化合物
CN1230431C (zh) 用作类胰蛋白酶抑制剂的芳基甲胺衍生物
CN1365281A (zh) 金属蛋白酶抑制剂
CN1658875A (zh) 用作组胺h3拮抗剂的1－(4－哌啶基)苯并咪唑酮
CN1642938A (zh) 新化合物
CN1662524A (zh) 用作组胺h3拮抗剂的吲哚衍生物
CN1211572A (zh) 趋化细胞因子受体－3拮抗剂
CN1684952A (zh) 用于治疗趋化因子介导的疾病的新的哌啶衍生物
CN1812980A (zh) 哌啶基－和哌嗪基－烷基氨基甲酸酯衍生物,其制备及治疗用途
CN1491208A (zh) 酰化的6,7,8,9-四氢-5h-苯并环庚烯基胺和它们作为药物的用途
CN1658874A (zh) 用作组胺h3拮抗剂的(1－4－哌啶基)苯并咪唑衍生物
CN1032438A (zh) 新的取代的n-(1-烷基-3-羟基-4-哌啶基)苯甲酰胺
HK1044337A1 (en) Amide compounds
CN1642913A (zh) 用作趋化因子受体活性(尤其是ccr5)调节剂的哌啶或8－氮杂－二环[3.2.1]辛－3－基衍生物
CN1921858A (zh) 哌啶基烷基氨基甲酸酯衍生物、其制备方法及其作为faah酶抑制剂的应用
CN1458922A (zh) 尿素衍生物及以其作为有效成分的粘连分子阻断剂
CN1114591C (zh) 环酰胺化合物
CN1993358A (zh) 作为趋化因子受体拮抗剂的噻唑衍生物
CN1173957C (zh) 取代的哌嗪酮及其治疗应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: AXYS PHARMACEUTICAL CORPORATION

Free format text: FORMER NAME OR ADDRESS: ARRIS PHARMACEUTICAL CORPORATION

CP01 Change in the name or title of a patent holder

Patentee after: AXYS Pharmaceuticals, Inc.

Patentee before: Arris Pharmaceutical Corp.

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee